Search Result

Results for "

advanced metastatic solid tumors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Akt (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (1) CD276/B7-H3 (1) Claudin (1) DGK (2) DNA/RNA Synthesis (1) Drug Isomer (1) EGFR (2) ERK (2) Glycosidase (1) IFNAR (2) Integrin (1) Interleukin Related (2) Notch (1) NTPDase (1) PARP (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) STING (2) TAM Receptor (2) TGF-beta/Smad (1) TNF Receptor (3) Topoisomerase (1) Transmembrane Glycoprotein (2) Trk Receptor (1) TROP2 (1) VEGFR (2)
By Research Areas:	Cancer (25) Inflammation/Immunology (2) Neurological Disease (1)

By Targets:

ADC Antibody (2)

Akt (1)

Antibody-Drug Conjugates (ADCs) (2)

Apoptosis (1)

CD276/B7-H3 (1)

Claudin (1)

DGK (2)

DNA/RNA Synthesis (1)

Drug Isomer (1)

EGFR (2)

ERK (2)

Glycosidase (1)

IFNAR (2)

Integrin (1)

Interleukin Related (2)

Notch (1)

NTPDase (1)

PARP (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (1)

STING (2)

TAM Receptor (2)

TGF-beta/Smad (1)

TNF Receptor (3)

Topoisomerase (1)

Transmembrane Glycoprotein (2)

Trk Receptor (1)

TROP2 (1)

VEGFR (2)

By Research Areas:

Cancer (25)

Inflammation/Immunology (2)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136174

RBN-2397 Maximum Cited Publications 17 Publications Verification	PARP	Cancer
RBN-2397 is a potent, accross species and orally active NAD ⁺ competitive inhibitor of PARP7 (IC₅₀<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

HY-152963

Tisotumab vedotin	Antibody-Drug Conjugates (ADCs)	Inflammation/Immunology Cancer
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .

HY-P991097

Pumitamig PM-8002; BNT-327	VEGFR PD-1/PD-L1	Cancer
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .

HY-175750

MOMA-341	DNA/RNA Synthesis	Cancer
MOMA-341 is a selective Werner RecQ like helicase (WRN) inhibitor. MOMA-341 binds to WRN at cysteine 727 through an allosteric and ATP-competitive binding mechanism. MOMA-341 has antitumor activity and can be used for advanced and metastatic solid tumors research .

HY-114358

Tamnorzatinib 2 Publications Verification ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR Notch	Cancer
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors .

HY-P99291

Etaracizumab LM609; MEDI-522	Integrin Apoptosis Akt	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG mAb. Etaracizumab is developed to target α_vβ₃+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofα_vβ₃-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991212

Berahyaluronidase alfa ALT-B4	Glycosidase	Cancer
Berahyaluronidase alfa (ALT-B4) is a recombinant hyaluronidase engineered from human hyaluronidase PH20. Berahyaluronidase alfa features favorable structural stability and enzymatic activity, and can be used to enhance drug absorption and dispersion in subcutaneous or intradermal administration .

HY-147218

PF-07265807 ARRY-067	TAM Receptor	Cancer
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 ⁺ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .

HY-153793

Alcudacigib DGKζ-IN-1	DGK IFNAR Interleukin Related ERK	Cancer
Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC₅₀ of 4.7 nM against human DGKζ and an IC₅₀ of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .

HY-P99812

Ragifilimab 1 Publications Verification INCAGN-1876	TNF Receptor	Inflammation/Immunology Cancer
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .

HY-153793A

Alcudacigib TFA DGKζ-IN-1 TFA	DGK IFNAR Interleukin Related ERK	Cancer
Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC₅₀ of 4.7 nM against human DGKζ and an IC₅₀ of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .

HY-176296

Vizenpistat SR-8541A	Phosphodiesterase (PDE) STING	Cancer
Vizenpistat (SR-8541A) is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer .

HY-163668

MK-2118	STING	Cancer
MK-2118 is a GMP-synthesized STING agonist with the potential to inhibit advanced/metastatic solid tumors or lymphomas. .

HY-P991223

NC762	Transmembrane Glycoprotein TNF Receptor	Cancer
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .

HY-P991371

PF-06478924 PF-06664178 antibody; RN926	TROP2	Cancer
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .

HY-P991093

NGM-707	Transmembrane Glycoprotein	Cancer
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors .

HY-157941A

(R,R)-ART0380	Drug Isomer	Cancer
(R,R)-ART0380 (Compound 38) is the enantiomer of ART0380 (HY-157941). ART0380 is a potent and selective ATR inhibitor. ART0380 can be used in studies of advanced or metastatic solid tumors .

HY-P990038

Eurestobart ES002023	NTPDase	Neurological Disease
Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors .

HY-P991635

PF-07329640	TNF Receptor	Cancer
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

HY-185683

Elfetabart drozuntecan DB-1311; BNT324	Antibody-Drug Conjugates (ADCs) Topoisomerase CD276/B7-H3	Cancer
Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate (ADC) targeting B7H3. Elfetabart drozuntecan conjugates a humanized anti-B7H3 IgG1 monoclonal antibody with a topoisomerase I inhibitor via a cleavable linker. Elfetabart drozuntecan exerts antitumor activity in solid tumors. Elfetabart drozuntecan can be used for the research of advanced/metastatic solid tumors .

HY-P992316

ATG-022 Antibody	Claudin ADC Antibody	Cancer
ATG-022 Antibody is a humanized monoclonal antibody targeting Claudin 18.2 (CLDN 18.2). ATG-022 Antibody binds with VcMMAE (HY-15575) to form an Antibody-Drug Conjugate (ADC). ATG-022 Antibody can be used for the research of advanced/metastatic solid tumors and gastric cancer .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

Cat. No.	Product Name	Target	Research Area	Image